Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,746.01
(
0.33%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 164743

Thursday, 01/09/2014 2:16:32 PM

Thursday, January 09, 2014 2:16:32 PM

Post# of 257265
Re: Interim phase-2 data on VX-135 + Daclatasvir

VRTX reports SVR4 rate of 83% (10/12) in high-dose cohort of open-label phase-2 study of VX-135 + BMY’s Daclatasvir in treatment-naïve GT1 patients:

http://finance.yahoo.com/news/vertex-announces-sustained-viral-response-133000898.html

Of the 12 patients in the 200mg* cohort of VX-135, one patient dropped out because of an SAE and one patient completed treatment but relapsed or didn’t respond to treatment.

The data from the 100mg cohort of VX-135 are worse (see press release). I stand by the assertion in #msg-90498491.

*FDA has a clinical hold on the 200mg dose of VX-135.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today